| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.4 | 3e-17 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.36 | 2e-14 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.56 | 8e-14 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | 0.35 | 7e-13 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.31 | 1e-12 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.4 | 2e-12 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.32 | 3e-12 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.32 | 2e-10 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.27 | 6e-10 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.4 | 5e-08 |